Compare CVKD & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVKD | IRIX |
|---|---|---|
| Founded | 2022 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7M | 20.2M |
| IPO Year | 2023 | 1996 |
| Metric | CVKD | IRIX |
|---|---|---|
| Price | $7.12 | $1.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | ★ 82.1K | 66.7K |
| Earning Date | 11-10-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $50,647,000.00 |
| Revenue This Year | N/A | $9.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.58 |
| 52 Week Low | $6.75 | $0.78 |
| 52 Week High | $22.90 | $1.89 |
| Indicator | CVKD | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 36.15 | 67.30 |
| Support Level | $6.75 | $0.95 |
| Resistance Level | $7.75 | $1.07 |
| Average True Range (ATR) | 1.00 | 0.06 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 10.78 | 85.19 |
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.